{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T03:47:34Z","timestamp":1778644054775,"version":"3.51.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T00:00:00Z","timestamp":1727481600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T00:00:00Z","timestamp":1727481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Mersin University Scientific Research Projects Unit","award":["BAP 2022-1-TP3-4563."],"award-info":[{"award-number":["BAP 2022-1-TP3-4563."]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"DOI":"10.1186\/s12894-024-01592-8","type":"journal-article","created":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T06:01:42Z","timestamp":1727503302000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Evaluation of serum fibronectin levels and fibronectin gene polymorphism in patients receiving intravesical BCG therapy for non-muscle invasive bladder cancer and its prognostic value"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6325-1534","authenticated-orcid":false,"given":"Ali","family":"Nebio\u011flu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7004-790X","authenticated-orcid":false,"given":"Rojda","family":"Tanr\u0131verdi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9873-4920","authenticated-orcid":false,"given":"Mert","family":"Ba\u015farano\u011flu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3256-8752","authenticated-orcid":false,"given":"Bar\u0131\u015f","family":"Saylam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9385-128X","authenticated-orcid":false,"given":"Erc\u00fcment","family":"Ulusoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8624-0149","authenticated-orcid":false,"given":"Murat","family":"Bozlu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7669-414X","authenticated-orcid":false,"given":"Erdem","family":"Akbay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0997-0260","authenticated-orcid":false,"given":"L\u00fcl\u00fcfer","family":"Tamer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2935-0760","authenticated-orcid":false,"given":"Semra","family":"Erdo\u011fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,28]]},"reference":[{"key":"1592_CR1","doi-asserted-by":"crossref","unstructured":"Wong MCS, Fung FDH, Leung C, Cheung WWL, Goggins WB, Ng CF. The global epidemiology of bladder cancer: a joinpoint regression analysis of its incidence and mortality trends and projection. Sci Rep. 2018;8.","DOI":"10.1038\/s41598-018-19199-z"},{"key":"1592_CR2","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.eururo.2012.07.033","volume":"63","author":"M Burger","year":"2013","unstructured":"Burger M, Catto JWF, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2013;63:234\u201341.","journal-title":"Eur Urol"},{"key":"1592_CR3","doi-asserted-by":"crossref","unstructured":"Barone B, Finati M, Cinelli F, Fanelli A, Del Giudice F, De Berardinis E et al. Bladder Cancer and risk factors: data from a multi-institutional long-term analysis on Cardiovascular Disease and Cancer Incidence. J Pers Med. 2023;13.","DOI":"10.3390\/jpm13030512"},{"key":"1592_CR4","doi-asserted-by":"crossref","unstructured":"Ferro M, T\u0103taru OS, Musi G, Lucarelli G, Abu Farhan AR, Cantiello F et al. Modified Glasgow Prognostic score as a predictor of recurrence in patients with high Grade Non-muscle invasive bladder Cancer undergoing intravesical Bacillus Calmette-Guerin Immunotherapy. Diagnostics (Basel). 2022;12.","DOI":"10.3390\/diagnostics12030586"},{"key":"1592_CR5","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1007\/s00262-023-03469-5","volume":"72","author":"M Santoni","year":"2023","unstructured":"Santoni M, Myint ZW, B\u00fcttner T, Takeshita H, Okada Y, Lam ET, et al. Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study. Cancer Immunol Immunother. 2023;72:2961\u201370.","journal-title":"Cancer Immunol Immunother"},{"key":"1592_CR6","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.euf.2021.01.003","volume":"8","author":"A Rizzo","year":"2022","unstructured":"Rizzo A, Mollica V, Massari F. Expression of programmed cell death Ligand 1 as a predictive biomarker in metastatic urothelial carcinoma patients treated with first-line Immune checkpoint inhibitors Versus Chemotherapy: a systematic review and Meta-analysis. Eur Urol Focus. 2022;8:152\u20139.","journal-title":"Eur Urol Focus"},{"key":"1592_CR7","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.juro.2007.03.034","volume":"178","author":"HB Grossman","year":"2007","unstructured":"Grossman HB, Gomella L, Fradet Y, Morales A, Presti J, Ritenour C, et al. A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer. J Urol. 2007;178:62\u20137.","journal-title":"J Urol"},{"key":"1592_CR8","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.juro.2007.03.028","volume":"178","author":"Y Fradet","year":"2007","unstructured":"Fradet Y, Grossman HB, Gomella L, Lerner S, Cookson M, Albala D, et al. A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study. J Urol. 2007;178:68\u201373.","journal-title":"J Urol"},{"key":"1592_CR9","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.eururo.2013.03.059","volume":"64","author":"M Burger","year":"2013","unstructured":"Burger M, Grossman HB, Droller M, Schmidbauer J, Hermann G, Dr\u01cegoescu O, et al. Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. Eur Urol. 2013;64:846\u201354.","journal-title":"Eur Urol"},{"key":"1592_CR10","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.eururo.2019.08.016","volume":"76","author":"M Babjuk","year":"2019","unstructured":"Babjuk M, Burger M, Comp\u00e9rat EM, Gontero P, Mostafid AH, Palou J, et al. European Association of Urology Guidelines on non-muscle-invasive bladder Cancer (TaT1 and Carcinoma in Situ) \u2013\u20092019 update. Eur Urol. 2019;76:639\u201357.","journal-title":"Eur Urol"},{"key":"1592_CR11","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1007\/s40273-014-0194-2","volume":"32","author":"C Yeung","year":"2014","unstructured":"Yeung C, Dinh T, Lee J. The health economics of bladder cancer: an updated review of the published literature. PharmacoEconomics. 2014;32:1093\u2013104.","journal-title":"PharmacoEconomics"},{"key":"1592_CR12","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.eururo.2015.10.024","volume":"69","author":"J Leal","year":"2016","unstructured":"Leal J, Luengo-Fernandez R, Sullivan R, Witjes JA. Economic burden of bladder Cancer across the European Union. Eur Urol. 2016;69:438\u201347.","journal-title":"Eur Urol"},{"key":"1592_CR13","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1007\/BF03262330","volume":"21","author":"MF Botteman","year":"2003","unstructured":"Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R. The health economics of bladder cancer: a comprehensive review of the published literature. PharmacoEconomics. 2003;21:1315\u201330.","journal-title":"PharmacoEconomics"},{"key":"1592_CR14","unstructured":"NCCN Guidelines for Bladder Cancer. (Version 3.2023). National Comprehensive Cancer Network. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1417. 2023. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1417. Accessed 8 Oct 2023."},{"key":"1592_CR15","doi-asserted-by":"publisher","first-page":"3861","DOI":"10.1242\/jcs.00059","volume":"115","author":"R Pankov","year":"2002","unstructured":"Pankov R, Yamada KM. Fibronectin at a glance. J Cell Sci. 2002;115:3861\u20133.","journal-title":"J Cell Sci"},{"key":"1592_CR16","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.matbio.2005.06.008","volume":"24","author":"Y Mao","year":"2005","unstructured":"Mao Y, Schwarzbauer JE. Fibronectin fibrillogenesis, a cell-mediated matrix assembly process. Matrix Biol. 2005;24:389\u201399.","journal-title":"Matrix Biol"},{"key":"1592_CR17","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1172\/JCI114434","volume":"85","author":"LR Kavoussi","year":"1990","unstructured":"Kavoussi LR, Brown EJ, Ritchey JK, Ratliff TL. Fibronectin-mediated Calmette-Guerin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response. J Clin Invest. 1990;85:62\u20137.","journal-title":"J Clin Invest"},{"key":"1592_CR18","doi-asserted-by":"crossref","unstructured":"Ratliffe TL, Kavoussi LR, Catalona WJ. Role of fibronectin in intravesical BCG therapy for superficial bladder cancer. J Urol. 1988;139.","DOI":"10.1016\/S0022-5347(17)42445-1"},{"key":"1592_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms21186542","volume":"21","author":"M Mancini","year":"2020","unstructured":"Mancini M, Righetto M, Zumerle S, Montopoli M, Zattoni F. The bladder EpiCheck Test as a non-invasive Tool based on the identification of DNA methylation in bladder Cancer cells in the urine: a review of published evidence. Int J Mol Sci. 2020;21:1\u20139.","journal-title":"Int J Mol Sci"},{"key":"1592_CR20","doi-asserted-by":"publisher","first-page":"6278","DOI":"10.1172\/JCI139597","volume":"130","author":"X Chen","year":"2020","unstructured":"Chen X, Zhang J, Ruan W, Huang M, Wang C, Wang H, et al. Urine DNA methylation assay enables early detection and recurrence monitoring for bladder cancer. J Clin Invest. 2020;130:6278\u201389.","journal-title":"J Clin Invest"},{"key":"1592_CR21","doi-asserted-by":"crossref","unstructured":"Sieverink CA, Batista RPM, Prazeres HJM, Vinagre J, Sampaio C, Le\u00e3o RR et al. Clinical Validation of a Urine Test (Uromonitor-V2\u00ae) for the Surveillance of Non-Muscle-Invasive Bladder Cancer Patients. Diagnostics (Basel). 2020;10.","DOI":"10.3390\/diagnostics10100745"},{"key":"1592_CR22","doi-asserted-by":"crossref","unstructured":"Piatti P, Chew YC, Suwoto M, Yamada T, Jara B, Jia XY et al. Clinical evaluation of bladder CARE, a new epigenetic test for bladder cancer detection in urine samples. Clin Epigenetics. 2021;13.","DOI":"10.1186\/s13148-021-01029-1"},{"key":"1592_CR23","doi-asserted-by":"crossref","unstructured":"Deng L, Chao H, Deng H, Yu Z, Zhao R, Huang L et al. A novel and sensitive DNA methylation marker for the urine-based liquid biopsies to detect bladder cancer. BMC Cancer. 2022;22.","DOI":"10.1186\/s12885-022-09616-y"},{"key":"1592_CR24","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1016\/j.juro.2016.12.096","volume":"197","author":"W Beukers","year":"2017","unstructured":"Beukers W, van der Keur KA, Kandimalla R, Vergouwe Y, Steyerberg EW, Boormans JL, et al. FGFR3, TERT and OTX1 as a urinary biomarker combination for surveillance of patients with bladder Cancer in a large prospective Multicenter Study. J Urol. 2017;197:1410\u20138.","journal-title":"J Urol"},{"key":"1592_CR25","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/S0022-5347(05)64659-9","volume":"168","author":"S Eissa","year":"2002","unstructured":"Eissa S, Swellam M, Sadek M, Mourad MS, Ahmady O, El, Khalifa A. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors. J Urol. 2002;168:465\u20139.","journal-title":"J Urol"},{"key":"1592_CR26","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1515\/CCLM.2003.165","volume":"41","author":"N Mutlu","year":"2003","unstructured":"Mutlu N, Turkeri L, Emerk K. Analytical and clinical evaluation of a new urinary tumor marker: bladder tumor fibronectin in diagnosis and follow-up of bladder cancer. Clin Chem Lab Med. 2003;41:1069\u201374.","journal-title":"Clin Chem Lab Med"},{"key":"1592_CR27","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1111\/j.1464-410X.2005.05357.x","volume":"95","author":"E Ioachim","year":"2005","unstructured":"Ioachim E, Michael M, Stavropoulos NE, Kitsiou E, Salmas M, Malamou-Mitsi V. A clinicopathological study of the expression of extracellular matrix components in urothelial carcinoma. BJU Int. 2005;95:655\u20139.","journal-title":"BJU Int"},{"key":"1592_CR28","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.urology.2004.09.028","volume":"65","author":"V Men\u00e9ndez","year":"2005","unstructured":"Men\u00e9ndez V, Fern\u00e1ndez-Su\u00e1rez A, Gal\u00e1n JA, P\u00e9rez M, Garc\u00eda-L\u00f3pez F. Diagnosis of bladder cancer by analysis of urinary fibronectin. Urology. 2005;65:284\u20139.","journal-title":"Urology"},{"key":"1592_CR29","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1007\/s00120-008-1825-z","volume":"47","author":"A Hegele","year":"2008","unstructured":"Hegele A, Kosche B, Schrader AJ, Sevinc S, Olbert PJ, Hofmann R, et al. [Transitional cell carcinoma of the bladder. Evaluation of plasma levels of cellular fibronectin as a stage-dependent marker]. Urologe A. 2008;47:1137\u201340.","journal-title":"Urologe A"},{"key":"1592_CR30","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s12032-010-9422-6","volume":"28","author":"S Eissa","year":"2011","unstructured":"Eissa S, Swellam M, Amin A, Balbaa ME, Yacout GA, El-Zayat TM. The clinical relevance of urine-based markers for diagnosis of bladder cancer. Med Oncol. 2011;28:513\u20138.","journal-title":"Med Oncol"},{"key":"1592_CR31","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1016\/j.clinbiochem.2013.05.064","volume":"46","author":"X Yang","year":"2013","unstructured":"Yang X, Huang H, Zeng Z, Zhao L, Hu P, He D, et al. Diagnostic value of bladder tumor fibronectin in patients with bladder tumor: a systematic review with meta-analysis. Clin Biochem. 2013;46:1377\u201382.","journal-title":"Clin Biochem"},{"key":"1592_CR32","doi-asserted-by":"crossref","unstructured":"Guszcz T, Sankiewicz A, Gorodkiewicz E. Application of surface plasmon resonance imaging biosensors for determination of fibronectin, laminin-5 and type IV collagen in serum of transitional bladder cancer patients. J Pharm Biomed Anal. 2023;222.","DOI":"10.1016\/j.jpba.2022.115103"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-024-01592-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12894-024-01592-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-024-01592-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T06:02:30Z","timestamp":1727503350000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcurol.biomedcentral.com\/articles\/10.1186\/s12894-024-01592-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,28]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1592"],"URL":"https:\/\/doi.org\/10.1186\/s12894-024-01592-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4573841\/v1","asserted-by":"object"}]},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,28]]},"assertion":[{"value":"13 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval for the research was obtained from the Mersin University Faculty of Medicine Local Ethics Committee with the decision dated 23.03.2022, numbered 2022\/200. Informed consent forms were signed by all individuals included in the study. It has been confirmed that all data were processed in accordance with relevant data protection regulations and patient confidentiality was maintained.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"210"}}